Safety and Immunogenicity of a Four Influenza Vaccines in Children Ages 6 Months Old to Less Than 48 Months Old
Public ClinicalTrials.gov record NCT02035696. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I/II, Randomized, Observer-Blind, Multicenter Study to Evaluate Immunogenicity and Safety of Four Influenza Vaccines in Healthy Pediatric Subjects 6 to < 48 Months of Age.
Study identification
- NCT ID
- NCT02035696
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Seqirus
- Industry
- Enrollment
- 671 participants
Conditions and interventions
Conditions
Interventions
- Trivalent influenza vaccine (TIVc) Biological
- Trivalent influenza vaccine-licensed Biological
Biological
Eligibility (public fields only)
- Age range
- 6 Months to 48 Months
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2013
- Primary completion
- May 31, 2014
- Completion
- Nov 30, 2014
- Last update posted
- Jul 9, 2018
2013 – 2014
United States locations
- U.S. sites
- 21
- U.S. states
- 12
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 116 | Phoenix | Arizona | — | — |
| Site 119 | Tucson | Arizona | — | — |
| Site 109 | Little Rock | Arkansas | — | — |
| Site 112 | Long Beach | California | — | — |
| Site 113 | Ontario | California | — | — |
| Site 117 | San Diego | California | — | — |
| Site 114 | West Covina | California | — | — |
| Site 107 | Thornton | Colorado | — | — |
| Site 111 | Miami | Florida | — | — |
| Site 108 | Miami Beach | Florida | — | — |
| Site 121 | Gainesville | Georgia | — | — |
| Site 101 | Omaha | Nebraska | — | — |
| Site 104 | Omaha | Nebraska | — | — |
| Site 105 | Omaha | Nebraska | — | — |
| Site 106 | Omaha | Nebraska | — | — |
| Site 103 | Youngstown | Ohio | — | — |
| Site 102 | Charleston | South Carolina | — | — |
| Site 115 | Houston | Texas | — | — |
| Site 110 | Salt Lake City | Utah | — | — |
| Site 118 | St. George | Utah | — | — |
| Site 120 | Spokane | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02035696, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 9, 2018 · Synced Jul 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02035696 live on ClinicalTrials.gov.